Dos Santos RG

Single-Dose Ayahuasca for Depressive and Anxiety Symptoms Associated With Cancer Diagnosis: A Single-Blind Feasibility Proof-of-Concept Trial.

Maekawa RM, Guerra LTL, Villanova B +8

Ibogaine as a double-edged sword: Developmental cardiotoxicity and neurobehavioral alterations in zebrafish.

de Oliveira AL, Abe FR, Dos Santos RG +2

Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study.

Rocha JM, Maekawa RM, Reis JAS +9

Classic psychedelics and personality: An updated systematic review.

Vicentini AB, de Paula CC, Silva Reis JA +3

ArticleKetamine

Safety and tolerance of oral ketamine: A systematic review.

Novaretti N, Pessoa RMP, Hallak JEC +2

Ayahuasca and Public Health III: Health Status of a Sample of Ayahuasca Ceremony Attenders in Portugal.

Teixeira PJ, Encantado J, Amaro HD +7

Effects of ayahuasca on neuropsychological performance and social cognition: A systematic review.

de Paula CC, Vicentini AB, Guerra LTL +3

Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling.

Ribeiro GSG, Paranhos BAPB, Dörr F +11

Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats.

Werle I, Guimarães FS, Dos Santos RG +2

Clinical pharmacology of ayahuasca: potential applications and future considerations.

Lopes Guerra LT, da Silva Dias IC, Hallak JEC +1

Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.

de Oliveira AL, de Oliveira DP, Dos Santos RG +1

Acute suicidal behavior following ayahuasca ingestion in a clinical trial setting: a case report.

Reis JAS, Rossi GN, Zacharias ABV +2

Ayahuasca: pharmacology, safety, and therapeutic effects.

Dos Santos RG, Hallak JEC

Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.

Chaves C, Dos Santos RG, Dursun SM +4

ArticleKetamine

Ketamine-induced altered states of consciousness: a systematic review of implications for therapeutic outcomes in psychiatric practices.

da Costa Gonçalves KT, de Tavares VDO, de Morais Barros ML +9

Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use: A Single-blind, Feasibility, Proof-of-Concept Trial.

Rodrigues LS, Reis JAS, Rossi GN +9

Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.

Fonseca AM, Dos Santos RG, de Medeiros LS +10

ArticleKetamine

Solvent-free parallel artificial liquid membrane extraction for drugs of abuse in plasma samples using LC-MS/MS.

Fabris AL, Pedersen-Bjergaard S, Øiestad EL +5

Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT<sub>2A</sub> and 5-HT<sub>1A</sub> receptors.

Werle I, Nascimento LMM, Dos Santos ALA +4

Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.

Ona G, Reverte I, Rossi GN +4

Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic.

Bouso JC, Révész D, Ona G +5

Interactive Effects of Ayahuasca and Cannabidiol in Social Cognition in Healthy Volunteers: A Pilot, Proof-of-Concept, Feasibility, Randomized-Controlled Trial.

Rossi GN, Rocha JM, Osório FL +10

Hallucinations and Hallucinogens: Psychopathology or Wisdom?

Bouso JC, Ona G, Kohek M +4

Classical Hallucinogens As Antidepressant Drugs: A Cautionary Approach.

Dos Santos RG, Rossi GN, Hallak JEC +2

Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.

Rodríguez-Cano BJ, Kohek M, Ona G +4

Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant.

Rossi GN, Guerra LTL, Baker GB +4

Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.

Rossi GN, Hallak JEC, Bouso Saiz JC +1

Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability.

Rossi GN, Dias ICDS, Baker G +4

Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials.

Dos Santos RG, Rocha JM, Rossi GN +10

Unveiling ayahuasca psychopharmacology: the accomplishments of Jordi Riba (1968-2020).

Dos Santos RG, Araujo DB, Sanches RF +1

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers.

Mendes Rocha J, Rossi GN, Osório FL +7

Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects.

Durante Í, Dos Santos RG, Bouso JC +1

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study.

Révész D, Ona G, Rossi GN +5

Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.

Rocha JM, Rossi GN, de Lima Osório F +7

Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.

Rodrigues LS, Rossi GN, Rocha JM +4

Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.

Dos Santos RG, Hallak JE, Baker G +1

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.

Dos Santos RG, Bouso JC, Rocha JM +2

Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy.

Dos Santos RG, Bouso JC, Hallak JE

Psychedelic Medicines in Major Depression: Progress and Future Challenges.

Bouso JC, Ona G, Dos Santos RG +1

Rapid and sustained decreases in suicidality following a single dose of ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial.

Zeifman RJ, Singhal N, Dos Santos RG +4

Polypharmacology or "Pharmacological Promiscuity" In Psychedelic Research: What Are We Missing?

Ona GS, Dos Santos RG, Hallak JEC +1

Europe PMC2020

Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination.

Jiménez-Garrido DF, Gómez-Sousa M, Ona G +4

Europe PMC2020

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.

Dos Santos RG, Hallak JEC

Europe PMC2020

Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer.

Dos Santos RG, Bouso JC, Hallak JEC

Translational evidence for ayahuasca as an antidepressant: what's next?

Dos Santos RG, Bouso JC

Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.

Rocha JM, Osório FL, Crippa JAS +4

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.

Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ +1

Europe PMC2018

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.

Palhano-Fontes F, Barreto D, Onias H +20

Psychedelics and Personality.

Aixalà M, Dos Santos RG, Hallak JEC +1

Europe PMC2018

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Dos Santos RG, Bouso JC, Hallak JEC

Europe PMC2017

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging.

Dos Santos RG, Osório FL, Crippa JAS +1

Europe PMC2016

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Dos Santos RG, Osório FL, Crippa JA +3

Europe PMC2016